Cytokine storm is a severe immune overreaction that can be triggered by viral infection & can lead to serious complications. Learn more about how #COVID19 related cytokine storm affects the lungs. https://t.co/vpbx6zHtvn pic.twitter.com/Tpsln8y4Xg
— Incyte (@Incyte) July 24, 2020
Together, we Solve On. by relentlessly pursuing #science to improve the lives of patients.
— Incyte (@Incyte) October 9, 2020
October is #NationalEczemaAwarenessMonth. We remain committed to addressing the unmet needs of those who have #atopicdermatitis. Learn about @nationaleczema's initiative & join us in raising awareness.
— Incyte (@Incyte) October 1, 2020
At Incyte, we Solve On. Today and every day we continue to innovate to find new solutions for patients, including those with rare cancers. #RareCancerDay
— Incyte (@Incyte) September 30, 2020
As #RareCancerDay approaches, learn more about our rare cancer pipeline and commitment to improving the lives of those living with rare cancers.
— Incyte (@Incyte) September 28, 2020
We're thrilled to announce that we've been recognized on @PHLBizJournal's #Soaring76 list as one of Philadelphia’s fastest-growing companies.
— Incyte (@Incyte) September 25, 2020
At Incyte, we Solve On. In our work, there's no finish line.
— Incyte (@Incyte) September 24, 2020
Take time today to learn more about chronic myeloid leukemia (#CML) and how you can support the community. CML Life offers resources dedicated to helping improve the lives of those affected by CML. #WorldCMLDay
— Incyte (@Incyte) September 22, 2020
Incyte is honored to fund the implementation of @MassGeneralNews' innovative project for the betterment of the graft-versus-host disease (#GVHD) community.
— Incyte (@Incyte) September 15, 2020
Myeloproliferative neoplasms (#MPNs) are a group of rare, chronic blood cancers. Together, let's support the MPN community by raising awareness of these devastating diseases. #MPNAwarenessDay
— Incyte (@Incyte) September 10, 2020
We’re honored to share that @american_skin1 has recognized our work in dermatology by selecting us as the recipient of the Global Impact Award in Biopharmaceutical Research and Medicine. Hear more from Jim Lee, Group Vice President and Head of Inflammation and Autoimmunity.
— Incyte (@Incyte) September 9, 2020
Today is #WLD20! #Leukemia is a type of cancer that affects white blood cells, the cells which typically fight infection. Find out more about @AcuteLeuk's initiative & help raise awareness.
— Incyte (@Incyte) September 4, 2020
We're proud to recognize the myeloproliferative neoplasm community in honor of the 10th anniversary of #BloodCancerAwarenessMonth, supporting activities that bring awareness to myeloproliferative neoplasms (#MPNs).
— Incyte (@Incyte) September 3, 2020
We’re continuing to advance Phase 3 trials of our investigational treatment for people w/ #COVID19 associated cytokine storm. The Delaware Journal of Public Health, in collaboration w/ Incyte, published details on the trial design of RUXCOVID & 369-DEVENT.
— Incyte (@Incyte) July 30, 2020
We’re excited to share that an Incyte-discovered medicine has been nominated for the 2020 #PrixGalien USA Awards from the @GalienFdn, which recognizes impactful 2020 global health innovation, in the Best Pharmaceutical Agent category.
— Incyte (@Incyte) July 24, 2020
We're presenting results from our cholangiocarcinoma patient survey via the virtual @curecc 2020 Annual Conference tomorrow at 12:15 pm ET. Register to hear the results.
— Incyte (@Incyte) July 22, 2020
Today at 10:00 am ET the design of our Phase 3 RUXCOVID trial will be presented as part of @AACR's Virtual Meeting: COVID-19 and Cancer. Visit the on-demand platform to learn more.
— Incyte (@Incyte) July 20, 2020
We are committed to supporting our patients, our colleagues & our business in a way that protects the environment & enhances the communities around us. Learn more about our Global Responsibility initiative.
— Incyte (@Incyte) July 14, 2020
#News: @TheLancet has published data from a randomized, controlled study on our investigational treatment for patients with #vitiligo.
— Incyte (@Incyte) July 9, 2020
At Incyte, we take the health of our employees very seriously & we're thrilled to be recognized as a finalist by @PHLBizJournal for the 2020 Healthiest Employer award. https://t.co/y81EeOm7WI pic.twitter.com/qBKZMp5gJY
— Incyte (@Incyte) June 25, 2020
Join us starting today at @AADSkin’s Virtual Meeting Experience, where we’ll be sharing data from our Atopic Dermatitis and Vitiligo programs with the scientific community. #AADVMX2020
— Incyte (@Incyte) June 12, 2020
We're presenting data from our Phase 2 study investigating the addition of PI3Kδ inhibition to JAK inhibition for patients with myelofibrosis. Visit @EHA_Hematology's library to review. #EHA25Virtual
— Incyte (@Incyte) June 12, 2020
This World Blood Cancer Day, visit @VoicesofMPN to explore online patient tools and resources that can be accessed from your own home. #wbcd
— Incyte (@Incyte) May 28, 2020
Learn more about the role of molecular profiling in helping doctors identify options for people with #cholangiocarcinoma.
— Incyte (@Incyte) April 24, 2020
J.G. Jones shares his myeloproliferative neoplasm (#MPN) diagnosis to bring attention to this rare type of cancer. Learn more about his experience.
— Incyte (@Incyte) April 16, 2020
Register for the Revolutionizing Atopic Dermatitis 2020 Virtual Symposium on Sunday, April 5th starting at 11:00 am ET, where data on our investigational therapy for patients with #atopicdermatitis will be shared via the live stream. @RevAtopicDerm
— Incyte (@Incyte) March 31, 2020
#News: @TheLancet has published a Phase 2 study, evaluating our investigational treatment for adults with previously treated, locally advanced or metastatic #cholangiocarcinoma.
— Incyte (@Incyte) March 24, 2020
The Incyte Ingenuity Award is now open for applications. Our Executive Vice President, General Manager, U.S., Barry Flannelly, sheds light on what opportunities this presents for the #GVHD community.
— Incyte (@Incyte) February 25, 2020
On this #WorldCCADay, we are proud to join organizations like @curecc to empower patients & caregivers affected by this disease. We recognize the HCPs who are aiding in the advancement of research. @WorldCCADay.
— Incyte (@Incyte) February 12, 2020
On this #WorldCCADay, our colleague & Medical Director Oncology, Luis R. Féliz Viñas, weighs in on the power of partnership to raise awareness for cholangiocarcinoma patients. @CCA_Alliance.
— Incyte (@Incyte) February 12, 2020
#DYK that #cholangiocarcinoma is most common in those 65 years old and above? Learn the symptoms of this rare cancer ahead of #WorldCCADay
— Incyte (@Incyte) February 11, 2020
Reflecting on #WorldCancerDay, we continue our commitment to take action against #cancer. Our team of researchers strives daily to create innovative medicines for patients in serious need. #IAmAndIWill
— Incyte (@Incyte) February 6, 2020
Check out our clinical trial resources to aid patients in making informed decisions.
— Incyte (@Incyte) December 27, 2019
Our short film, "Beyond Blue", will be screened at the #DISORDER Film Festival. Watch here to learn more. #mpnsn https://t.co/ORsNDdtz7H
— Incyte (@Incyte) November 9, 2019
We’re proud to share that our CEO, Hervé Hoppenot, has been recognized by @PHLBizJournal as one of the Top 25 Most Admired CEOs of 2019—an outstanding and well-deserved honor! https://t.co/qWFy8qanRN
— Incyte (@Incyte) October 25, 2019
Our Chief Scientific Officer, Dash Dhanak, shares his perspective on what it means for Incyte to be recognized as a #SCTopEmployer by @ScienceCareers. #LifeAtIncyte pic.twitter.com/l7MiZgmrrR
— Incyte (@Incyte) October 25, 2019
To Barry Flannelly, Executive Vice President, General Manager, U.S., #LifeAtIncyte offers the opportunity to discover, develop and deliver for patients. Hear more on what it means to be recognized as a #SCTopEmployer by @ScienceCareers. pic.twitter.com/LEozjKKfbE
— Incyte (@Incyte) October 24, 2019
Jim Lee, Group VP & Head of Inflammation & Autoimmunity, explains how we're utilizing our expertise of the JAK pathway as we seek to address unmet needs for people with #vitiligo. #EADV2019 pic.twitter.com/32qbf70pTm
— Incyte (@Incyte) October 10, 2019
Our Chief Medical Officer, Steven Stein, explains how our inflammation & autoimmunity group uncovered the potential to address unmet needs in #vitiligo. Watch to learn more. pic.twitter.com/bXgIPxZ1Cp
— Incyte (@Incyte) October 9, 2019
Our Group VP & Head of Inflammation & Autoimmunity, Jim Lee, shares perspective on our commitment to patients and how it's led to the study of immune-mediated conditions.
— Incyte (@Incyte) October 9, 2019
Today, we recognize the first #RareCancerDay hosted by @RareDiseases & emphasize our commitment to the #rarecancer community, including those living with #MPNs & other serious diseases.
— Incyte (@Incyte) October 1, 2019
Ahead of #RareCancerDay, we recognize the importance of sharing stories among the #rarecancer community to help people living with an MPN, like Matt, feel heard. Read more about Matt's journey here: https://t.co/Yaej3uXbmB.
— Incyte (@Incyte) September 30, 2019
Live at #ESMO19: Dr. Arndt Vogel, M.D., Senior Consultant and Professor at Hannover Medical School, offers his perspective on how physicians can identify patients with #cholangiocarcinoma who have FGFR2 fusions or rearrangements. pic.twitter.com/AmPkHTx9FB
— Incyte (@Incyte) September 27, 2019
Hear from our Chief Medical Officer, Steven Stein, on how we're digging deeper into our #science to potentially address the unmet need for people living with #vitiligo. pic.twitter.com/hePcaNpjyl
— Incyte (@Incyte) September 23, 2019
What comes to mind when our Head of HR, Paula Swain, thinks about #LifeAtIncyte? The people and patient impact. pic.twitter.com/LeOGLe7OaR
— Incyte (@Incyte) September 17, 2019
Our discovery approach ladders up to a portfolio that is strategically coherent and synergy-rich with molecules that are designed to be optimized for their intended use. https://t.co/q9t3OsScSx
— Incyte (@Incyte) August 14, 2019
Life-saving clinical advances and discovery wouldn’t be possible without the basis of foundational research. Incredible new findings from @NIH on early stage cancer diagnosis https://t.co/qdJTBRyUfT
— Incyte (@Incyte) August 12, 2019
Our culture encourages our teams to be flexible, ask questions and challenge each other in order to innovate and deliver for patients. pic.twitter.com/kcfdW6ILoE
— Incyte (@Incyte) July 18, 2019
New: Lilly and @Incyte are sharing additional data showing reduced time to recovery and improved clinical outcomes for patients with #COVID19 infection requiring oxygen. Learn more: https://t.co/TrN0RoYbj4 pic.twitter.com/UgJSc5OLBx
— Eli Lilly and Company (@LillyPad) October 8, 2020
FDA granted Priority Review to investigational treatment for patients with a specific mutation in advanced non-small cell lung cancer. #NovartisNews #NSCLC
— Novartis News (@NovartisNews) February 11, 2020
Herve Hoppenot, President & CEO of #DEBIO member company @Incyte, provides an inside look at the #technology & #innovation happening at the #Delaware based #pharmaceutical #research facility! pic.twitter.com/kSbzXNnHRE
— Delaware Bio (@Delaware_Bio) July 29, 2019
Our discovery capabilities within the field of immunotherapy open distinct opportunities to target diverse mechanisms.
— Incyte (@Incyte) December 23, 2019
Today and every day, we are committed to supporting those impacted by #DLBCL. #BCAM pic.twitter.com/5CjdJ6bbKF
— Incyte (@Incyte) September 17, 2020
In collaboration with @MorphoSys, we are proud to offer a new targeted treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (#DLBCL). pic.twitter.com/jn7HkJW9Vi
— Incyte (@Incyte) August 5, 2020
We're thrilled to open our new European headquarters in the Swiss city of Morges. We are looking forward to the increased collaboration & innovation this building will foster. pic.twitter.com/1R7PxlAQA9
— Incyte (@Incyte) July 6, 2020
Kimberly Boyd sheds light on the need for #vitiligo patient support and why she advocates for the vitiligo community, as a patient and member of the @StepUp4Vitiligo team. #VirtualWorldVitiligoDayUSA pic.twitter.com/WZLPqmBEWP
— Incyte (@Incyte) June 25, 2020
Erika Page, Living Dappled Founder & Editor, was inspired to start her own advocacy organization to help uplift & educate others with #vitiligo. #VitiligoAwarenessMonth pic.twitter.com/KAtpB5r8Hx
— Incyte (@Incyte) June 22, 2020
We're pleased to be a part of the virtual 25th @EHA_Hematology Annual Congress to continue sharing #oncology data with the scientific community. #EHA25 pic.twitter.com/trBmbTQPEI
— Incyte (@Incyte) June 10, 2020
Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapies, shares what the recent FDA milestone means for adults with previously treated, unresectable locally advanced or metastatic #cholangiocarcinoma. pic.twitter.com/fWUOBJebac
— Incyte (@Incyte) April 23, 2020
As #WorldCCADay approaches, join us in recognizing and supporting those affected by #cholangiocarcinoma. https://t.co/iqgkDrYfrV
— Incyte (@Incyte) February 12, 2020
We are proud to share that our CEO, Hervé Hoppenot, has been recognized by the @PHLBizJournal as one of the Most Admired CEOs in 2019. His leadership guides our mission to support patients and the communities we serve. pic.twitter.com/upDV0MXA4e
— Incyte (@Incyte) December 4, 2019
We're at the @KeyWestFilmFest where our short film "Beyond Blue" shows a glimpse inside Barbara's life living with an #MPN. We're proud to have created a film that supports the #raredisease community & raises awareness of MPNs. #KWFF pic.twitter.com/WLfAIcLWHF
— Incyte (@Incyte) November 21, 2019
We’re proud to have been named a #SCTopEmployer again this year. Hear from our Head of HR, Paula Swain, on why we believe in work-life balance for all of our employees. #LifeAtIncyte pic.twitter.com/pDijMMCuuE
— Incyte (@Incyte) November 5, 2019
We're honored to partner with advocacy organizations like @curecc to help raise awareness & offer support for the #rarecancer community. #RareCancerDay pic.twitter.com/OKmwboLCGl
— Incyte (@Incyte) October 1, 2019
We’ve been recognized as a @PHLBizJournal #Soaring76 – one of greater Philadelphia’s fastest-growing companies. Great to join our local industry colleagues tonight at the recognition ceremony. pic.twitter.com/CNNnBn0d5i
— Incyte (@Incyte) September 26, 2019
Thank you @RMHDelaware for having us! Great to give back to our local community. https://t.co/xR0kzcdCoK
— Incyte (@Incyte) September 6, 2019